A Phase 1b Study to Assess the Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors
Phase of Trial: Phase I/II
Latest Information Update: 27 Dec 2018
At a glance
- Drugs Pamiparib (Primary) ; Temozolomide (Primary)
- Indications Advanced breast cancer; Gastric cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Small cell lung cancer; Solid tumours
- Focus Adverse reactions
- Sponsors BeiGene
- 22 Oct 2018 According to a BeiGene media release, data (n=40) from this study were presented at the European Society for Medical Oncology (ESMO) 2018 Congress.
- 08 Oct 2018 According to a BeiGene media release, results from this trial will be presented at the European Society for Medical Oncology (ESMO)2018 Congress.
- 12 Sep 2017 Trial design of the study presented at the 42nd European Society for Medical Oncology Congress.